PUBLISHER: The Business Research Company | PRODUCT CODE: 1949825
PUBLISHER: The Business Research Company | PRODUCT CODE: 1949825
Biologics CDMO Global Market Report 2026
A biologics contract development and manufacturing organization (CDMO) is a service provider that assists pharmaceutical companies in the development and production of biologic drugs, including vaccines, blood and blood components, allergens, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins.
The main cell types used in biologics CDMOs are mammalian and non-mammalian. Mammalian cells are derived from mammals and are commonly used in the production of biologics and cell-based therapies due to their ability to produce complex proteins and maintain post-translational modifications. The product types include biologics and biosimilars.
Tariffs have affected the biologics CDMO market by increasing the cost of importing raw materials, lab equipment, and specialized cell culture media, which has put pressure on operational expenses. The mammalian cell and biosimilar production segments, particularly in Asia-Pacific and North America, are most impacted due to their reliance on global supply chains. While these tariffs pose challenges, they have also encouraged local sourcing, investment in domestic manufacturing capabilities, and accelerated adoption of innovative, cost-efficient biologics production technologies.
The biologics cdmo market research report is one of a series of new reports from The Business Research Company that provides biologics cdmo market statistics, including biologics cdmo industry global market size, regional shares, competitors with a biologics cdmo market share, detailed biologics cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the biologics cdmo industry. This biologics cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The biologics cdmo market size has grown rapidly in recent years. It will grow from $24.15 billion in 2025 to $27.56 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to rise in biologics research, advancements in cell culture technologies, increasing prevalence of chronic diseases, growth of biosimilar pipelines, government support for biopharma manufacturing.
The biologics cdmo market size is expected to see rapid growth in the next few years. It will grow to $48.07 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to surge in gene and cell therapy development, adoption of automation and robotics in CDMO processes, expansion of global biologics manufacturing capacity, increasing investment in precision medicine, rising demand for cost-effective biologics. Major trends in the forecast period include expansion of biologics cdmo services, growth in mammalian cell-based production, increase in outsourcing of gene therapy manufacturing, adoption of advanced bioprocessing techniques, rising demand for biosimilars.
The surge in demand for cell and gene therapy is expected to drive the growth of the biologic CDMO market going forward. Cell and gene therapies are innovative medical approaches that use living cells or genetic material to target the underlying causes of disease at the cellular or genetic level, offering potential treatments for conditions that are difficult to manage or incurable with traditional pharmaceuticals. The demand for these therapies is increasing due to their ability to provide novel treatments by addressing the root genetic or cellular causes of diseases. Biologic CDMOs offer expertise in handling living cells, viral vectors, and genetic material, enabling the safe and efficient production of cell and gene therapies while helping biopharmaceutical companies navigate regulatory requirements and technical challenges, thereby facilitating the transition from research to clinical application. For instance, in March 2024, according to IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, global spending on cell and gene therapies rose to $5.9 billion in 2023, representing a 38% increase from 2022. Therefore, the surge in demand for cell and gene therapy is driving the growth of the biologic CDMO market.
Major companies in the biologics CDMO market are focusing on developing technologically advanced solutions, such as novel cell lines, to enhance biopharmaceutical development and manufacturing efficiency. This technology enables the production of therapeutic antibodies with improved potency, addressing challenges in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturer specializing in the pharmaceutical and biotechnology sectors, launched GS Effex cell lines, designed to produce antibodies that are 100% fucose-free and exhibit increased potency without compromising other performance attributes. These stable, scalable, and productive cell lines support therapeutic development from discovery-stage research through commercial manufacturing, overcoming key immunotherapy R&D challenges.
In December 2024, Novo Holdings A/S, a Denmark-based investment company, completed the acquisition of Catalent, Inc., for an undisclosed amount. Through this acquisition, Novo Holdings aims to expand its portfolio in the contract development and manufacturing organization (CDMO) sector, enhance global manufacturing capabilities, and support the growth of innovative drug development solutions. Catalent, Inc. is a US-based CDMO that provides advanced delivery technologies, development, and manufacturing services for drugs, biologics, and consumer health products.
Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics
North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the biologics cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The biologics CDMO market consist of revenues earned by entities by providing services such as process development, analytical development, cell line development, supply chain management, and fill-finish services. The biologics CDMO market also includes sales of monoclonal antibodies, recombinant proteins, antisense and molecular therapy, and vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biologics CDMO Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses biologics cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for biologics cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biologics cdmo market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
- Markets Covered:1) By Cell Type: Mammalian; Non-Mammalian
- 2) By Product Type: Biologics; Biosimilars
- 3) By Service Type: Drug Substance Manufacturing; Drug Product (Fill-Finish) Manufacturing; Process Development; Analytical & Quality Testing Services
- Subsegments:
- 1) By Mammalian: Chinese Hamster Ovary (CHO) Cells; Human Embryonic Kidney (HEK) Cells; Other Mammalian Cells
- 2) By Non-Mammalian: Yeast Cells; Bacterial Cells; Insect Cells; Other Non-Mammalian Cells
- Companies Mentioned: Lonza Group Ltd; Samsung Biologics Co Ltd; WuXi Biologics Cayman Inc; Catalent Inc; Thermo Fisher Scientific Inc; Boehringer Ingelheim International GmbH; Emergent BioSolutions Inc; Grifols SA; AbbVie Inc; Novartis AG; Sandoz International GmbH; Fujifilm Holdings Corporation; AGC Inc; JSR Corporation; Shenzhen Hepalink Pharmaceutical Co Ltd; Kemwell Biopharma Pvt Ltd; Bora Pharmaceuticals Co Ltd; Binex Co Ltd; 3P Biopharmaceuticals SLU; Cytovance Biologics
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: Word, PDF or Interactive Report
- + Excel Dashboard
- Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
Table of Contents
1. Executive Summary
- 1.1. Key Market Insights (2020-2035)
- 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
- 1.3. Major Factors Driving the Market
- 1.4. Top Three Trends Shaping the Market
2. Biologics CDMO Market Characteristics
- 2.1. Market Definition & Scope
- 2.2. Market Segmentations
- 2.3. Overview of Key Products and Services
- 2.4. Global Biologics CDMO Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
- Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
- 2.4.4. Market Attractiveness Scoring and Interpretation
- 2.4.5. Strategic Implications and Recommendations
3. Biologics CDMO Market Supply Chain Analysis
- 3.1. Overview of the Supply Chain and Ecosystem
- 3.2. List Of Key Raw Materials, Resources & Suppliers
- 3.3. List Of Major Distributors and Channel Partners
- 3.4. List Of Major End Users
4. Global Biologics CDMO Market Trends And Strategies
- 4.1. Key Technologies & Future Trends
- 4.1.1 Artificial Intelligence & Autonomous Intelligence
- 4.1.2 Biotechnology, Genomics & Precision Medicine
- 4.1.3 Industry 4.0 & Intelligent Manufacturing
- 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
- 4.2. Major Trends
- 4.2.1 Expansion Of Biologics Cdmo Services
- 4.2.2 Growth In Mammalian Cell-Based Production
- 4.2.3 Increase In Outsourcing Of Gene Therapy Manufacturing
- 4.2.4 Adoption Of Advanced Bioprocessing Techniques
- 4.2.5 Rising Demand For Biosimilars
5. Biologics CDMO Market Analysis Of End Use Industries
- 5.1 Pharmaceutical Companies
- 5.2 Biotechnology Companies
- 5.3 Research Institutions
- 5.4 Contract Manufacturing Organizations
- 5.5 Hospitals & Clinics
6. Biologics CDMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Biologics CDMO Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
- 7.1. Global Biologics CDMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 7.2. Global Biologics CDMO Market Size, Comparisons And Growth Rate Analysis
- 7.3. Global Biologics CDMO Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
- 7.4. Global Biologics CDMO Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Biologics CDMO Total Addressable Market (TAM) Analysis for the Market
- 8.1. Definition and Scope of Total Addressable Market (TAM)
- 8.2. Methodology and Assumptions
- 8.3. Global Total Addressable Market (TAM) Estimation
- 8.4. TAM vs. Current Market Size Analysis
- 8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Biologics CDMO Market Segmentation
- 9.1. Global Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Mammalian, Non-Mammalian
- 9.2. Global Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Biologics, Biosimilars
- 9.3. Global Biologics CDMO Market, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Drug Substance Manufacturing, Drug Product (Fill-Finish) Manufacturing, Process Development, Analytical & Quality Testing Services
- 9.4. Global Biologics CDMO Market, Sub-Segmentation Of Mammalian, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells
- 9.5. Global Biologics CDMO Market, Sub-Segmentation Of Non-Mammalian, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells
10. Biologics CDMO Market Regional And Country Analysis
- 10.1. Global Biologics CDMO Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- 10.2. Global Biologics CDMO Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Biologics CDMO Market
- 11.1. Asia-Pacific Biologics CDMO Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 11.2. Asia-Pacific Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Biologics CDMO Market
- 12.1. China Biologics CDMO Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 12.2. China Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Biologics CDMO Market
- 13.1. India Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Biologics CDMO Market
- 14.1. Japan Biologics CDMO Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 14.2. Japan Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Biologics CDMO Market
- 15.1. Australia Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Biologics CDMO Market
- 16.1. Indonesia Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Biologics CDMO Market
- 17.1. South Korea Biologics CDMO Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 17.2. South Korea Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Biologics CDMO Market
- 18.1. Taiwan Biologics CDMO Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 18.2. Taiwan Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Biologics CDMO Market
- 19.1. South East Asia Biologics CDMO Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 19.2. South East Asia Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Biologics CDMO Market
- 20.1. Western Europe Biologics CDMO Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 20.2. Western Europe Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Biologics CDMO Market
- 21.1. UK Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Biologics CDMO Market
- 22.1. Germany Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Biologics CDMO Market
- 23.1. France Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Biologics CDMO Market
- 24.1. Italy Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Biologics CDMO Market
- 25.1. Spain Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Biologics CDMO Market
- 26.1. Eastern Europe Biologics CDMO Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 26.2. Eastern Europe Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Biologics CDMO Market
- 27.1. Russia Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Biologics CDMO Market
- 28.1. North America Biologics CDMO Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 28.2. North America Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Biologics CDMO Market
- 29.1. USA Biologics CDMO Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 29.2. USA Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Biologics CDMO Market
- 30.1. Canada Biologics CDMO Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 30.2. Canada Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Biologics CDMO Market
- 31.1. South America Biologics CDMO Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 31.2. South America Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Biologics CDMO Market
- 32.1. Brazil Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Biologics CDMO Market
- 33.1. Middle East Biologics CDMO Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 33.2. Middle East Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Biologics CDMO Market
- 34.1. Africa Biologics CDMO Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 34.2. Africa Biologics CDMO Market, Segmentation By Cell Type, Segmentation By Product Type, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Biologics CDMO Market Regulatory and Investment Landscape
36. Biologics CDMO Market Competitive Landscape And Company Profiles
- 36.1. Biologics CDMO Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
- 36.2. Biologics CDMO Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
- 36.3. Biologics CDMO Market Company Profiles
- 36.3.1. Lonza Group Ltd Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Samsung Biologics Co Ltd Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. WuXi Biologics Cayman Inc Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Catalent Inc Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
37. Biologics CDMO Market Other Major And Innovative Companies
- Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics
38. Global Biologics CDMO Market Competitive Benchmarking And Dashboard
39. Key Mergers And Acquisitions In The Biologics CDMO Market
40. Biologics CDMO Market High Potential Countries, Segments and Strategies
- 40.1 Biologics CDMO Market In 2030 - Countries Offering Most New Opportunities
- 40.2 Biologics CDMO Market In 2030 - Segments Offering Most New Opportunities
- 40.3 Biologics CDMO Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies
41. Appendix
- 41.1. Abbreviations
- 41.2. Currencies
- 41.3. Historic And Forecast Inflation Rates
- 41.4. Research Inquiries
- 41.5. The Business Research Company
- 41.6. Copyright And Disclaimer
